{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-051263","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.386388+00:00","generated_at":"2026-06-01T05:21:53.795042+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA and EMA back MoonLake's Phase 3 program for sonelokimab in psoriatic arthritis","bullets":["FDA and EMA unanimously supported MoonLake's proposed Phase 3 IZAR program for sonelokimab in PsA.","Phase 3 design: ~1,500 patients across two trials (IZAR-1 bio-naïve, IZAR-2 TNF-IR with risankizumab reference).","Doses 60mg and 120mg; primary endpoint ACR50 at week 16; first patient Q4 2024, topline readout end-2026.","Follows positive FDA/EMA feedback for HS Phase 3 VELA program; Phase 3 HS recruitment already started.","Phase 2 ARGO data plus IZAR intended to support BLA and EU MAA for sonelokimab in PsA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-051263","json":"https://secwatch.observer/filing/0001213900-24-051263.json","markdown":"https://secwatch.observer/filing/0001213900-24-051263.md","text":"https://secwatch.observer/filing/0001213900-24-051263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024051263/0001213900-24-051263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024051263/ea0207582-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:21:53.795042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}